QUALITY INDICATORS: Standards of care based on CPG’s

Goal

- To define and assess quality indicators from institutions of SSN and SSN International Advisory Board members
- the QI are reported overall for entire cohort, and each for Bone, STS superficial and STS deep

Inclusion criteria

- all WHO defined intermediate and malignant mesenchymal (bone and soft tissue) tumors referred to the respective institutions from 01.01.2020 until 30.06.2020

Quality indicators / Outcome measures

QI-1: appropriate local imaging before biopsy/treatment initiation (yes/no)
QI-1.1: Diagnosis of malignant tumor considered/noted in the radiological report (yes/no)
QI-2: time from 1st patient contact to biopsy (if performed)
QI-3: type of biopsy: FNA, tru-cut (CT- or US-guided), open incisional, excisional biopsy, enucleation/whoops
QI-4: time from biopsy to establishing diagnosis (1st path review & reference review)
   - date of biopsy (D1); date of 1st path report (DBx1st); date of final path report from 1st institute (DBxFinal); date of submission for path review (DRevSub); date of final path review (DRevFinal)
   - QI-4.1: Performance of 1st path institute (D1 to DBx1st)
   - QI-4.2: Performance of review process (DRevSub to DRevFinal)
   - QI-4.3: Performance of Path Analysis of Network (D1 to DRevFinal)
   → if 1st institute equals reference institute, then QI-4.2 = QI-4.3
   → to assess discrepancies of 1st and reference pathologists, we report on a.) no discrepancy, b.) discrepancy minor (not relevant for therapy eg grading, variant) / major (benign versus malignant, tumor type etc); and c.) not applicable
QI-5: time from biopsy until sarcoma board presentation
QI-6: biopsy before initiation of treatment (yes/no)
QI-7: biopsy performed in the center where the patient is operated: (yes/no)
QI-8: extent of disease at diagnosis (localized/locally advanced incl. whoops/metastatic)
QI-9: time from SB to initiation of treatment
QI-10: margin status (R0, R1, R2) at definitive surgery (STS)
QI-11: preoperative radiation therapy: (yes/no)
QI-12: postoperative radiation therapy: (yes/no)
QI-13: neo-adjuvant chemotherapy: (yes/no)
QI-14: adjuvant chemotherapy (yes/no)
QI-15: local relapse: yes/no
   If yes: date of relapse
QI-16: local recurrence: yes/no within 1st year of tumor resection (Bone)
QI-17: metastatic relapse: yes/no
   If yes: date of relapse
QI-18: Latest follow-up: no evidence of disease (NED); alive with disease (AWD); dead of disease (DOD); dead of other reasons (DOR); no assessment possible; lost to follow-up; other status; unknown
   date of latest follow-up:

To include in a next step:

QI-XY: percentage of patients with response (RECIST/Choi/diffusion) to neoadjuvant radiotherapy (STS).
   → ALC: Complex to obtain in general: it is not a quality indicator but an information for outcome
QI-XY: percentage of response of patients with response (pathological) to neoadjuvant chemotherapy (osteosarcoma, Ewing tumors):
   → ALC: same remarks than above
QI-XY: percentage of Infection rates in surgical scar/wound in STS
QI-XY: percentage of Infection rates in surgical scar/wound in malignant bone tumor
QI-XY: deep infection rate in patients with prosthesis or osteosynthesis